Fulgent Genetics (FLGT) Q2 2026 earnings review
Acquisitions Mask Organic Decline While Billing Failures Crush Guidance
Fulgent's Q2 paints a troubling picture. While revenue grew 20% sequentially to $85.4M, this was entirely driven by the integration of the Bako and StrataDx acquisitions, which masked the structural hole left by the loss of their largest customer. The bottom line is deteriorating rapidly: Non-GAAP gross margin plummeted to 31.3% (down from 44.2% YoY). More alarmingly, management slashed FY26 revenue guidance by $15M at the midpoint, citing 'processing delays' from a revenue cycle management system transition. The underlying laboratory business is struggling with basic execution, overshadowing the long-term potential of the therapeutics pipeline.
🐂 Bull Case
FID-007 showed a 61.9% Objective Response Rate (ORR) in Phase 2 for Head & Neck cancer and secured an ASCO presentation. This validates Fulgent's transition toward a high-upside biotech model.
Management bought back 1.5 million shares for $23.8M in Q2, building on the 2.6 million shares retired in Q1. The shrinking float provides technical support and signals extreme management conviction.
🐻 Bear Case
A 'revenue cycle management and billing system' transition broke down, impacting collection rates severely enough to force a $15M cut to FY26 revenue guidance. This is a massive unforced error.
Despite management touting AI-driven 'Eziopath' efficiencies, GAAP gross margins completely collapsed from 42.1% a year ago to 30.1% today. Fixed costs are crushing profitability on the legacy base.
⚖️ Verdict: 🔴
Bearish. M&A is hiding severe organic revenue decay, margins are in freefall, and basic back-office billing failures are eroding cash collections. The biotech pipeline is promising, but the core cash-cow laboratory business is currently misfiring.
Key Themes
Revenue Cycle Management Failure
The most critical revelation this quarter is the implementation failure of Fulgent's new billing system. Management explicitly stated that 'processing delays impacting our collection rate' forced them to revise FY26 revenue guidance down. This indicates that tests are being run, but the company cannot effectively bill or collect for them. If collections remain stalled, the cash burn will accelerate far beyond current projections.
AI Efficiency Claims Contradicted by Margin Freefall
CEO Ming Hsieh claimed the company is 'seeing a real impact from our AI tools with improved efficiency and quality' using their Eziopath platform. However, the financial data completely contradicts this positive narrative. Non-GAAP gross margin fell to 31.3% from 44.2% YoY, and Non-GAAP operating margin plummeted to -26.2% from -9.4%. AI may be improving turnaround times, but it is failing to protect the bottom line against volume loss and fixed-cost deleverage.
Bako and StrataDx Carrying the Top Line
The $85.4M revenue print (+20.1% sequentially) represents the first full quarter including the Bako and StrataDx acquisitions (closed March 17, 2026). Without this inorganic injection, sequential revenue would have been significantly worse, exposing the full impact of their departed anchor customer. The expanded dermatopathology and anatomic pathology footprint is now the company's primary defense mechanism for the top line.
FID-007 Validates Biotech Pivot
The therapeutic pipeline continues to be a bright spot. FID-007 (nanoencapsulated paclitaxel) presented at ASCO, showing a 61.9% Objective Response Rate (ORR) and an 85.7% Disease Control Rate in heavily pre-treated Head & Neck cancer patients. With a 1-year Overall Survival rate of 63.4% and a manageable safety profile, the 505(b)(2) accelerated regulatory pathway looks increasingly viable. Management is successfully executing the transition from a diagnostics lab to an oncology biotech.
Macro Impact: $106M Tax Refund Still Hostage to IRS Delays
A severe macro-driven liquidity bottleneck persists: Fulgent is still waiting on a $106.1M federal tax refund delayed by 'constrained resources at the IRS' (stemming from previous government shutdowns). This represents nearly 20% of their current cash balance. While management assumes receipt by December 31, 2026, the ongoing delay heightens liquidity risk as the company simultaneously funds M&A, aggressive buybacks, and clinical trials.
Other KPIs
Cash bleed is accelerating. The balance dropped from $604.6M in 26Q1 and $755.5M at the end of 2025. This $204M six-month reduction was driven by the $56.4M Bako/StrataDx acquisition, $63.9M in YTD share repurchases, and expanding operating losses. The delayed $106M IRS refund is critical to replenishing the balance sheet.
Accelerating. Up 12.1% YoY from $43.8M in 25Q2. The cost structure is inflating just as organic revenues decline, driven by the integration of the Bako/StrataDx sales teams and continued R&D spend for the FID-007 and FID-022 clinical trials.
Guidance
Decelerating. This is a severe downward revision from the prior $350.0M target. At the midpoint ($335M), it implies a meager 3.8% YoY growth compared to FY25's $322.7M. Given that Bako/StrataDx were expected to add ~$53M this year, the organic core business is deeply contracting.
Reversing. The loss profile is widening dramatically. Previous guidance was for a non-GAAP loss of $1.59 per share. The new guidance translates to a loss of $2.22 to $2.35 per share. Management's inability to control costs against the billing-induced revenue shortfall is destroying the bottom line.
Key Questions
Billing System Resolution Timeline
You cited the transition of the revenue cycle management system as the driver for the revenue guidance cut. Exactly how much uncollected revenue is currently trapped in accounts receivable, and when do you expect normal collection rates to resume?
Organic Growth Baseline
With the downward revision to $330-$340M, and assuming Bako/StrataDx still contribute their expected $53M, this implies the legacy Fulgent business is shrinking over 10% YoY. Is that math correct, and what is the floor for the organic business?
Capital Allocation Priority Shift
You've spent nearly $64M on buybacks year-to-date while cash balances have dropped by $200M and the $106M tax refund remains delayed. Will you pause the buyback program until the billing issues are resolved and the IRS check clears?